Fate Therapeutics Highlights Presentation Of Late-Breaking Preclinical Data Highlighting Unique Advantages Of Clonal Master Engineered iPSC Lines For Off-The-Shelf CAR T-cell Therapy At 2019 AACR Annual Meeting
Benzinga Newsdesk